Synapse - Ronglai Shen

Results (205)

A phase II study of pemetrexed (P) plus gemcitabine (G) in patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)

Meeting Abstract

Pfister, D. G.; Haque, S.; Stambuk, H.; Lisa, D. M.; Shen, R.; Carlson, D.; Fury, M. G.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Use of PET-measured response in involved mediastinal lymph nodes to predict overall survival (OS) in non-small cell lung cancer (NSCLC) patients treated with induction therapy (IT) and surgery

Meeting Abstract

Barnett, S.; Plourde, G.; Zheng, J.; Pietanza, M.; Akhurst, T. J.; Downey, R. J.; Kris, M. G.; Shen, R.; Rusch, V. W.; Park, B. J.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

Journal Article

Politi, K.; Fan, P. D.; Shen, R.; Zakowski, M.; Varmus, H.
Disease Models & Mechanisms (2010)

Fulltext@MSK | Save

Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/ IV nonsmall cell lung cancer

Journal Article

Janjigian, Y. Y.; Mcdonnell, K.; Kris, M. G.; Shen, R.; Sima, C. S.; Bach, P. B.; Rizvi, N. A.; Riely, G. J.
Cancer (2010)

Fulltext@MSK | Save

Phase II study of bevacizumab (B) plus cisplatin (C) plus intensity-modulated radiation therapy (IMRT) for locoregionally advanced head and neck squamous cell cancer (HNSCC): Preliminary results

Meeting Abstract

Pfister, D. G.; Lee, N. Y.; Sherman, E.; Lisa, D.; Carlson, D.; Stambuk, H.; Shen, R.; Kraus, D.; Shah, J.; Fury, M. G.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations

Meeting Abstract

Janjigian, Y. Y.; Park, B. J.; Kris, M. G.; Miller, V. A.; Riely, G. J.; Zheng, J.; Dycoco, J. P.; Shen, R.; Azzoli, C. G.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Operative outcomes using bevacizumab, docetaxel, and cisplatin as induction therapy in patients with operable lung cancer

Meeting Abstract

Finley, D. J.; Shen, R.; Rizvi, N. A.; Rusch, V. W.; Kris, M. G.; on behalf of the MSKCC Thoracic Disease Management Team
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results

Meeting Abstract

Fury, M. G.; Sherman, E.; Stambuk, H.; Haque, S.; Lisa, D.; Shen, R.; Carlson, D.; Pfister, D. G.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

EGFR T790M-driven murine lung tumors respond to dual EGFR targeting with cetuximab and BIBW-2992

Meeting Abstract

Regales, L.; Gong, Y.; Politi, K.; Shen, R.; Spassova, M.; Ouerfelli, O.; Pao, W.
Cancer Research (2009)

Fulltext@MSK | Save

EGFR T790M decreases growth potential of lung tumor cells with drug-sensitive EGFR mutant alleles in the absence of drug selection

Meeting Abstract

Chmielecki, J.; Foo, J.; Somwar, R.; Regales, L.; Vivanco, I.; Shen, R.; Michor, F.; Pao, W.
Cancer Research (2009)

Fulltext@MSK | Save